Maximal diameter of any one hepatocellular carcinoma > 15 cm
Upper age limit of =< 18 years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
Patients must have confirmed hepatocellular carcinoma (HCC) by histopathology or imaging criteria according to AASLD guidelines.
Confirmed diagnosis of hepatocellular carcinoma (HCC)
Subjects must have a diagnosis of measurable advanced or metastatic hepatocellular carcinoma; advanced HCC is defined as disease not amenable to surgery, ablation, transplant, or embolic therapy
Histologically confirmed diagnosis of hepatocellular carcinoma (mixed HCC/cholangiocarcinoma is allowed)
Hepatocellular carcinoma;
HCC (unresectable hepatocellular carcinoma) histopathological diagnosis confirmation based on tumor tissue
Confirmed hepatocellular carcinoma (HCC) by one of the following: \r\n* Histopathology\r\n* One radiographic technique that confirms a lesion >= 1 cm with arterial hypervascularization with washout on delayed phase
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Patients with hepatocellular carcinoma do not need to have histologic confirmation of disease as long as they meet the radiologic criteria for diagnosis of hepatocellular carcinoma (HCC) (evidence of arterial phase enhancement with corresponding venous or delayed phase wash out)
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Patients must have advanced disease that is not amenable for resection or transplantation, and that is not treatable with liver directed modalities such as radiofrequency ablation or transarterial chemoembolization
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Patients are not required to have failed sorafenib
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Ascites that is not medically controlled or that required a therapeutic paracentesis within last 3 months
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Any episode of hepatic encephalopathy within the previous 6 months
COHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Variceal bleeding within last 6 months
Histologically or cytologically confirmed hepatocellular carcinoma or biliary tract cancer.
Progressed on, be intolerant of, or refused sorafenib (for hepatocellular carcinoma [HCC]), second line treatment and beyond for cholangiocarcinoma or gemcitabine-based chemotherapy for biliary tract cancer.
Histologic or cytologic diagnosis of unresectable, locally advanced and/or metastatic hepatocellular carcinoma (HCC) not amenable to curative surgery, transplantation, or ablative therapies based upon assessment of treating investigator
Confirmed unresectable or metastatic hepatocellular carcinoma; confirmation either by histologic confirmation or accepted radiographic criteria
Diagnosis of primary liver malignancy including hepatocellular carcinoma (HCC) or cholangiocarcinoma by characteristic imaging findings on computed tomography (CT) or MRI, clinical presentation, and/or pathologic confirmation of diagnosis; subjects with other current or prior malignancies are eligible for this study
Diagnosis of hepatocellular carcinoma
Pathologic diagnosis of hepatocellular carcinoma (including fibrolamellar variants and biphenotypic tumors with a hepatocellular carcinoma [HCC] component)
Patients with diagnoses of hepatocellular carcinoma (HCC) according to European Association for the Study of Liver disease (EASL) criteria for diagnosis; regional lymphadenopathy will be allowed\r\n* Any virus status accepted (e.g. hepatitis C, etc.)\r\n* Any prior liver treatment
Colorectal, hepatocellular, gallbladder, cholangiocarcinoma, neuroendocrine, melanomas, hematological and central nervous system (CNS) malignancies;
Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.
Advanced, unresectable hepatocellular carcinoma (unsuitable for resection, transplant or ablation)
Any one hepatocellular carcinoma > 15 cm
Total maximal sum of hepatocellular carcinomas or a single conglomerate HCC > 20 cm
Subjects with advanced hepatocellular carcinoma (HCC) with no curative option
Patient must have advanced hepatocellular carcinoma; fibrolamellar HCC is not allowed; hepatocellular carcinoma should be confirmed by at least one of the following:\r\n* Tissue diagnosis\r\n* The presence of one or more liver lesions measuring >= 2 cm in longest diameter, showing characteristic arterial enhancement and venous washout using arterial-phase contrast enhanced imaging, and a clinical history of cirrhosis
Diagnosis of hepatocellular carcinoma, cholangiocarcinoma, or liver metastasis from any histology
Part 2 Group B is restricted to HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).
Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:\r\n* Histologically confirmed\r\n* Magnetic resonance imaging (MRI) or computerized tomography (CT) findings consistent with hepatocellular carcinoma\r\n* Alpha fetoprotein (AFP) > 400 ng/mL AND evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI
Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required
Patients must have a diagnosis of hepatocellular carcinoma confirmed by at least one of the following: \r\n* Histological confirmation; \r\n* Imaging results consistent with cirrhosis and at least one solid liver lesion of > 2 cm with early enhancement and delayed washout (American Association for the Study of Liver Diseases [AASLD] criteria for diagnosis of hepatocellular carcinoma [HCC]);\r\n* Alpha fetoprotein level > 400 ng/mL and evidence of at least one solid liver lesion > 2 cm, regardless of specific imaging characteristics on magnetic resonance imaging (MRI)
Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods\r\n* Pathologically confirmed hepatocellular carcinoma (HCC) by biopsy, OR\r\n* HCC > 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced magnetic resonance imaging (MRI) or computed tomography (CT), OR\r\n* Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alpha fetoprotein (AFP) greater than 200 ng/mL
Patient diagnosed with hepatocellular carcinoma and listed for orthotopic liver transplantation at the participating institution in accordance with Organ Procurement and Transplantation Network (OPTN) guidelines
Patients with hepatocellular carcinoma will be excluded from this study
Subjects with hepatocellular carcinoma must have received sorafenib as one of the standard treatment options prior to being enrolled into the study
Subject has a confirmed pathologic diagnosis of Hepatocellular carcinoma (HCC) according to the American Association for the Study of Liver Diseases (AASLD) Guidelines.
Subject has received more than 2 previous systemic therapies for Hepatocellular carcinoma (HCC).
Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration
Patients with hepatocellular carcinoma are eligible for this trial; hepatocellular carcinoma is defined as having at least one of the following:\r\n* Biopsy proven hepatocellular carcinoma (HCC); or\r\n* A discrete hepatic tumor(s) as defined by the Barcelona criteria – for cirrhotic patients, > 1 cm with arterial hypervascularity and venous or delayed phase washout on computed tomography (CT) or MRI
If the patient is determined to be cirrhotic (based on criteria outlined earlier), the patient must have an ultrasound done within 6 months prior to enrollment with no evidence of hepatocellular carcinoma
Has a HCC diagnosis confirmed by radiology, histology or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).
Must have histologically or cytologically confirmed diagnosis of HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).
Chronic hepatitis (except for subjects with hepatocellular carcinoma)
Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
Hepatocellular carcinoma (HCC)\r\n* Not eligible for curative attempt resection or liver transplant
Histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
Locoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4 weeks prior to the baseline scan
Cohort 2: Participants must have hepatocellular carcinoma (HCC). These participants should have Child-Pugh stage A.
Subjects of 18 years or older (men and women) with histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
Patients with hepatocellular carcinoma may be eligible provided they have AST and ALT that are ? 5.0 x ULN.
Platelets ? 100 x 10^9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ? 75 x 10^9/L.
Have mixed hepatocellular biliary tract cancer histology.
For Cohort 1: has histologically or cytologically confirmed diagnosis of HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) based on pathology report
For Cohort 2: has an HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)
Platelets ? 100 x 10^9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ? 75 x 10^9/L.
Patients with the diagnosis of hepatocellular carcinoma (HCC) currently being evaluated for liver transplantation and considered for downstaging
History of recurrent bacterial infections unrelated to hepatocellular carcinoma (HCC) (particularly skin or lung)
Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.
Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)
Histologically/cytologically verified, non-resectable, recurrent, or metastatic biliary tract carcinoma including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma; combined cholangiocarcinoma and hepatocellular carcinoma is allowed
Subject has a confirmed pathologic diagnosis of Hepatocellular carcinoma according to the American Association for the Study of Liver Diseases Guidelines.A biopsy performed at screening may serve as a diagnostic biopsy for subjects with radiographic diagnosis.
Histologic diagnosis of liver-confined fibrolamellar or non-fibrolamellar hepatocellular carcinoma (HCC)
Advanced unresectable hepatocellular carcinoma with branch portal vein thrombosis (confirmed by non-invasive criteria EASL/AASLD, mandatory by histology in non-cirrhotic patients); can be naive or recurrent HCC after curative treatment (> 6 months before randomization)
Patients (except those with hepatocellular carcinoma) must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor or lymphoma that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effective; patients with hepatocellular carcinoma do not require biopsy confirmation; a liver mass with raised alpha-fetoprotein level (>= 500 ng/mL), consistent radiographic changes, and serology and viral deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) measurements consistent with chronic hepatitis will be sufficient to identify hepatocellular carcinoma without the need for pathologic confirmation of the diagnosis; patients with hepatocellular carcinoma must still, however, have disease that has failed standard therapy; having chronic hepatitis B or C will not exclude patients from participating
Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)
Subjects must have histologically or cytologically confirmed advanced solid tumor. However, Hepatocellular Carcinoma (HCC) subjects are allowed without histological confirmation as long as there is radiological diagnosis as per standard criteria
Histologically documented hepatocellular carcinoma
Histologically or cytologically confirmed hepatocellular carcinoma that is metastatic, unresectable, or recurrent.
Patients who have a diagnosis of hepatocellular carcinoma made through radiologic imaging may be eligible, provided they meet the criteria according to the American Association for the Study of Liver Disease, AASLD (Bruix and Sherman, 2005; Bruix and Sherman, 2011)
Cytological or histological confirmed diagnosis of advanced hepatocellular or renal cell carcinoma; HCC patients should not be amenable to treatment with surgery or to orthotopic liver transplant (Phase I)
Subjects with hepatocellular carcinoma
Hepatocellular Carcinoma (HCC) --Histologic or cytologic diagnosis of hepatocellular carcinoma
Patients diagnosed with hepatocellular carcinoma, or who have a history of biliary sepsis within the past 2 years
Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriate
PATIENT: Biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma, cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year
Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
Patients will have one of the following diseases: primary hepatocellular cancer, hepatobiliary cancer, or metastatic disease to the liver
Prior known or suspected hepatocellular carcinoma
Only participants found to express high levels (immunohistochemistry [IHC] score 3 and above) of gamma-OHPdG (gamma-OHPdG-high hepatocellular carcinoma [HCC]) in baseline liver biopsy will be enrolled to receive Polyphenon E treatment
Hepatocellular carcinoma
Patients with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or metastatic liver cancer planned to receive definitive doses of radiation or surgical resection are eligible
Scheduled for TACE treatment of a hepatocellular carcinoma (HCC) mass (lesions reported as Liver Imaging Reporting and Data Systems 4B or 5 or Organ Procurement and Transplantation Network 5a or 5b)
Subjects must have a diagnosis of hepatocellular carcinoma (HCC) and a treatment plan to undergo radioembolization therapy with Y-90 at Indiana University Health Hospital
Histopathologic or imaging and clinical features of tumor(s) diagnostic for hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and Data System (LI-RADS) 4 or greater
Locoregional treatment of hepatocellular carcinoma within the prior 3 months or chemotherapy within the previous 3 months
Subjects must have verified unresectable hepatocellular carcinoma (HCC), diagnosed on the basis of clinical and imaging criteria
Participants must have histologically or cytologically confirmed hepatocellular carcinoma OR have an imaging study that demonstrates a focal hepatic lesion with imaging features diagnostic of hepatocellular carcinoma